The drug is of great benefit to patients with AD by decreasing the expression of NLRP3 inflammasome genes to hamper the assembly of NLRP3 inflammasome, and down-regulating ERK1/2 and AKT phosphorylation to enhance Aβ autophagy (60). The gene discussed is NLRP3; the disease is Alzheimer disease.